# CENGN

ALTIS LABS INNOVATION HIGHLIGHT

ALTIS LABS

COMPANY OVERVIEW

Altis Labs is a clinical information company applying artificial intelligence to medical imaging to predict patient outcomes. Altis' software platform Nota enables clinicians and researchers to operationalize medical imaging data and leverage predictive insights at scale. The team includes leading machine learning engineers, biopharma R&D executives, clinicians, and business operators on a mission to improve patient outcomes.

LOCATION: TORONTO, ON

TECHNOLOGY

Data Centre and Cloud

Dougal Martin, Director of Communications
ALTIS LABS dougal@altislabs.com
altislabs.com

Rick Penwarden, Sr. Manager, Marketing
CENGN rick.penwarden@cengn.ca
cengn.ca/projects

IMPROVED PATIENT PREDICTIONS

It takes more than $2.5 billion and over 10 years to bring a single cancer drug to market. Less than 10% of phase 1 cancer drugs go on to receive regulatory approval, and most failures are due to the inability to demonstrate efficacy. Surrogate endpoints are most-often used to measure efficacy, but these can lack clinical meaningfulness and don't necessarily translate into clinical benefit. Data interpretation standards like RECIST 1.1. are the basis for surrogate endpoints but yield discordance of up to 52%, leading to flawed representation of treatment effect plus trial delays of over 4 months.

ALTIS LABS OFFERS NOTA

Altis Labs developed Nota, a cloud-based clinical information platform, to enable medical imaging data ingestion and automated outcome predictions so that biopharma can better understand clinical trial data. Nota's predictions help researchers enhance clinical trial design, shorten timelines, and anticipate clinical endpoints more accurately. In lung cancer patients, Altis' algorithms showed a 48% improvement in outcome predictions over the current standard, showcasing its power to transform the healthcare industry.

UTILIZING INFRASTRUCTURE FOR IMPROVED PREDICTION ALGORITHMS

Altis Labs used CENGN's infrastructure to train Nota's new algorithm on lesion detection and assessment. In this project, Altis integrated cutting-edge approaches that improved the ability to detect, classify, and segment tumours in the lungs. Through the project, Altis improved the lesion detection algorithm's overall accuracy and improved workflow speed for their internal radiology team.

> "We did a few months' worth of development in weeks because of our access to CENGN's platform."

Dougal Martin

Director of Communications, Altis Labs